Impact of ureido/carboxypenicillin resistance on the prognosis of ventilator-associated pneumonia due to Pseudomonas aeruginosa

Critical Care

Volumn 15, Issue 2, 2011, Pages

  Kaminski, Catherine ^a   Timsit, Jean François ^b,c   Dubois, Yohann ^b   Zahar, Jean Ralph ^c,d   Garrouste Orgeas, Maïté ^c,e   Vesin, Aurélien ^c   Azoulay, Elie ^c,f   Feger, Céline ^g   Dumenil, Anne Sylvie ^h   Adrie, Christophe ⁱ   Cohen, Yves ^j   Allaouchiche, Bernard ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b HÔPITAL MICHALLON   (France)

^c INSTITUT ALBERT BONNIOT   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e SAINT JOSEPH HOSPITAL   (France)

^f SAINT LOUIS HOSPITAL   (France)

^g Outcomerea   (France)

^h HÔPITAL ANTOINE BÉCLÈRE   (France)

ⁱ DELAFONTAINE HOSPITAL   (France)

^j AVICENNE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBOXYPENICILLIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; IMIPENEM; PENICILLIN G DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; UNCLASSIFIED DRUG; UREIDOPENICILLIN; ANTIINFECTIVE AGENT; CARBENICILLIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL COLONIZATION; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RISK FACTOR; SEPTIC SHOCK; VENTILATOR ASSOCIATED PNEUMONIA; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECT; FRANCE; LENGTH OF STAY; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; STATISTICS; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; CARBENICILLIN; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; FRANCE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 79953789742     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10136     Document Type: Article

References (38)

1. NNIS National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004, 32:470-485. NNIS.
2. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
3. REA-RAISIN Annual report 2009. , http://www.cclinparisnord.org/REACAT/REA2009/rea_raisin_resultats2009.pdf
4. Passador L, Cook JM, Gambello MJ, Rust L, Iglewski BH. Expression of Pseudomonas aeruginosa virulence genes requires cell-to-cell communication. Science (New York, NY) 1993, 260:1127-1130.
5. Singh G, Wu B, Baek MS, Camargo A, Nguyen A, Slusher NA, Srinivasan R, Wiener-Kronish JP, Lynch SV. Secretion of Pseudomonas aeruginosa type III cytotoxins is dependent on pseudomonas quinolone signal concentration. Microb Pathog 2010, 49:196-203. 10.1016/j.micpath.2010.05.013, 20570614.
6. Kohler T, Guanella R, Carlet J, van Delden C. Quorum sensing-dependent virulence during Pseudomonas aeruginosa colonisation and pneumonia in mechanically ventilated patients. Thorax 2010, 65:703-710. 10.1136/thx.2009.133082, 20685744.
7. Hauser AR, Cobb E, Bodi M, Mariscal D, Valles J, Engel JN, Rello J. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002, 30:521-528. 10.1097/00003246-200203000-00005, 11990909.
8. Kung VL, Ozer EA, Hauser AR. The accessory genome of Pseudomonas aeruginosa. Microbiol Mol Biol Rev 2010, 74:621-641. 10.1128/MMBR.00027-10, 21119020.
9. Combes A, Luyt CE, Fagon JY, Wolff M, Trouillet JL, Chastre J. Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia. Intensive Care Med 2006, 32:1970-1978. 10.1007/s00134-006-0355-7, 16957901.
10. Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002, 34:1047-1054. 10.1086/339488, 11914992.
11. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
12. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963. 10.1001/jama.270.24.2957, 8254858.
13. Timsit JF, Fosse JP, Troche G, De Lassence A, Alberti C, Garrouste-Orgeas M, Bornstain C, Adrie C, Cheval C, Chevret S. Calibration and discrimination by daily Logistic Organ Dysfunction scoring comparatively with daily Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients. Crit Care Med 2002, 30:2003-2013. 10.1097/00003246-200209000-00009, 12352033.
14. Zahar JR, Nguile-Makao M, Francais A, Schwebel C, Garrouste-Orgeas M, Goldgran-Toledano D, Azoulay E, Thuong M, Jamali S, Cohen Y, de Lassence A, Timsit JF. Predicting the risk of documented ventilator-associated pneumonia for benchmarking: construction and validation of a score. Crit Care Med 2009, 37:2545-2551. 10.1097/CCM.0b013e3181a38109, 19623046.
15. OUTCOMEREA: the matching N:M macro using the SAS software. , http://www.outcomerea.org/Telecharger-document/286-Matching-NM.html
16. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa Isolates: Occurence Rates, Antimicrobial Susceptibility Patterns, and Molecular Typing in the Global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001, 32:S146-155. 10.1086/320186, 11320454.
17. Vincent JL. Microbial resistance: lessons from the EPIC study. European Prevalence of Infection. Intensive Care Med 2000, 26:S3-8. 10.1007/s001340051111, 10786951.
18. Hirataka Y, Srikumar R, Poole K, Gotoh N, Suematsu T, Kohno S, Kamihira S, Hancock RE, Speert DP. Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa. J Exp Med 2002, 196:109-118. 10.1084/jem.20020005, 2194012, 12093875.
19. Sanchez P, Linares JF, Ruiz-Diez B, Campanario E, Navas A, Baquero F, Martinez JL. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J Antimicrob Chemother 2002, 50:657-664. 10.1093/jac/dkf185, 12407121.
20. Linares JF, Lopez JA, Camafeita E, Albar JP, Rojo F, Martinez JL. Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa. J Bacteriol 2005, 187:1384-1391. 10.1128/JB.187.4.1384-1391.2005, 545608, 15687203.
21. Hocquet D, Berthelot P, Roussel-Delvallez M, Favre R, Jeannot K, Bajolet O, Marty N, Grattard F, Mariani-Kurkdjian P, Bingen E, Husson MO, Couetdic G, Plésiat P. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother 2007, 51:3531-3536. 10.1128/AAC.00503-07, 2043289, 17682106.
22. Jeannot K, Elsen S, Köhler T, Attree I, van Delden C, Plésiat P. Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. Antimicrob Agents Chemother 2008, 52:2455-2462. 10.1128/AAC.01107-07, 2443911, 18474583.
23. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, Cayuela A, Rello J. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007, 35:1888-1895. 10.1097/01.CCM.0000275389.31974.22, 17581492.
24. Kang CI, Kim SH, Kim HB, Park SW, Choe YJ, Oh MD, Kim EC, Choe KW. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003, 37:745-751. 10.1086/377200, 12955633.
25. Clec'h C, Timsit JF, De Lassence A, Azoulay E, Alberti C, Garrouste-Orgeas M, Mourvilier B, Troche G, Tafflet M, Tuil O, Cohen Y. Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med 2004, 30:1327-1333. 10.1007/s00134-004-2292-7, 15197443.
26. Nguile-Makao M, Zahar JR, Francais A, Tabah A, Garrouste-Orgeas M, Allaouchiche B, Goldgran-Toledano D, Azoulay E, Adrie C, Jamali S, Clec'h C, Souweine B, Timsit JF. Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models. Intensive Care Med 2010, 36:781-789. 10.1007/s00134-010-1824-6, 20232046.
27. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005, 49:1306-1311. 10.1128/AAC.49.4.1306-1311.2005, 1068618, 15793102.
28. Blot S, Vandewoude K, De Bacquer D, Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis 2002, 34:1600-1606. 10.1086/340616, 12032895.
29. Raymond DP, Pelletier SJ, Crabtree TD, Evans HL, Pruett TL, Sawyer RG. Impact of antibiotic-resistant gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med 2003, 31:1035-1041. 10.1097/01.CCM.0000060015.77443.31, 12682469.
30. Zahar JR, Clec'h C, Tafflet M, Garrouste-Orgeas M, Jamali S, Mourvillier B, De Lassence A, Descorps-Declere A, Adrie C, Costa de Beauregard MA, Azoulay E, Schwebel C, Timsit JF, . Outcomerea Study Group Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia?. Clin Infect Dis 2005, 41:1224-1231. 10.1086/496923, 16206094, Outcomerea Study Group.
31. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006, 50:43-48. 10.1128/AAC.50.1.43-48.2006, 1346794, 16377665.
32. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999, 43:1379-1382. 89282, 10348756.
33. Harris AD, Perencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA. Risk factor for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 2002, 46:854-858. 10.1128/AAC.46.3.854-858.2002, 127481, 11850272.
34. Reinhardt A, Kohler T, Wood P, Rohner P, Dumas JL, Ricou B, van Delden C. Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. Antimicrob Agents Chemother 2007, 51:1341-1350. 10.1128/AAC.01278-06, 1855521, 17261619.
35. El Amari EB, Chamot E, Auckenthaler R, Pechère JC, van Delden C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001, 33:1859-1864. 10.1086/324346, 11692297.
36. Sugimura M, Maseda H, Hanaki H, Nakae T. Macrolide antibiotic-mediated downregulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008, 52:4141-4144. 10.1128/AAC.00511-08, 2573159, 18676884.
37. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009, 22:582-610. 10.1128/CMR.00040-09, 2772362, 19822890.
38. Paramythiotou E, Lucet JC, Timsit JF, Vanjak D, Paugam-Burtz C, Trouillet JL, Belloc S, Kassis N, Karabinis A, Andremont A. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004, 38:670-677. 10.1086/381550, 14986251.